NanoViricides (OTC:NNVC), a nanobio-pharmaceutical drug maker, said on Tuesday that its President Anil Diwan will present at a conference in Boston today, speaking about large molecules and biologics delivery.
The Partnership Opportunities in Drug Delivery Conference is being held at the Omni Parker Hotel in Boston, today.
Diwan will focus on the building-block-based tailor-made customization capabilities of the nanoviricides platform technology that has allowed rapid development of its drug candidates.
NanoViricides has also developed skin cream and lotion, eye drops, ophthalmic gels, and injectables based on this platform with very little formulation development required.
Additionally, he will present a summary of the company’s nanoviricides platform technology, its drug pipeline as well as recent successes with animal studies for its influenza therapeutic FluCide.
Further, the company added that it has no explanation for the recent drop in its stock price.
"Management believes the company is making significant progress in all of its initiatives. All of its drug programs are moving forward towards regulatory pathway satisfactorily," the company said.
NanoViricides is a development stage company that is creating special purpose nanomaterials for viral therapy.
The company is developing drugs against a number of viral diseases including H1N1 swine flu, HIV, oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, Dengue fever, Hepatitis C, Rabies, and Ebola virus, among others.
Recently, NanoViricides said that it is working on enabling current good manufacturing practices (cGMP) capability to produce its drug candidates. The cGMP process is required when NanoViricides is ready to file an Investigational New Drug application to the FDA.
Additionally, the company said that it has chosen NV-INF-1 in its anti-influenza drug program FluCide to develop for a regulatory submission both domestically and internationally.
Proactiveinvestors is a leading multi-media news organisation, investor portal and events management business with offices in New York, Sydney, Toronto, Frankfurt and London.
No comments:
Post a Comment